Brief: ImmunoPrecise Antibodies Says AI-Designed GLP-1 Peptides Surpass Semaglutide In Receptor Activation
12/06/2025 13:35
June 12 (Reuters) - Immunoprecise Antibodies Ltd IPA.O: IMMUNOPRECISE ANTIBODIES LTD - AI-DESIGNED GLP-1 PEPTIDES SURPASS SEMAGLUTIDE IN RECEPTOR ACTIVATION IMMUNOPRECISE ANTIBODIES LTD - FIVE AI-OPTIMIZED PEPTIDE SEQUENCES TESTED AGAINST GLP-1 ANALOGS Source text: ID:nBw2SwhRPa Further company coverage: IPA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mindwalk Holdings
See all newsBrief: Mindwalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp reports results for the quarter ended July 31 - Earnings Summary
Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
MindWalk Holdings Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: MindWalk Showcases Reefiq™ For Ai Drug Discovery At AMD Advancing Ai